CorMedix Inc. Announces Proposed Public Offering of Common Stock

Core Viewpoint - CorMedix Inc. plans to offer and sell $85.0 million of its common stock in an underwritten public offering, with a potential additional 15% option for underwriters [1][2] Group 1: Offering Details - The offering is subject to market conditions, and there is no assurance regarding its completion or terms [1] - RBC Capital Markets is acting as the sole bookrunner for the offering [2] - The net proceeds will be used for general corporate purposes, including working capital and research expenses [2] Group 2: Regulatory Information - The securities are being offered under a shelf registration statement filed with the SEC on May 6, 2024, and declared effective on May 22, 2024 [3] - A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and available on their website [4] Group 3: Company Overview - CorMedix is focused on developing therapeutic products for life-threatening conditions, with its lead product DefenCath® approved by the FDA on November 15, 2023 [6] - DefenCath was commercially launched in inpatient settings in April 2024 and in outpatient settings in July 2024 [6] - The company plans to commence clinical studies in Total Parenteral Nutrition and Pediatric populations in 2025 [6]